Lawrence Steinman

CIK: 0001132679

Transaction Breakdown

Open Market Buys (P)1 (14.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (85.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

KTTA

Pasithea Therapeutics Corp.

Director

ATNF

180 Life Sciences Corp.

Director

BCAB

BioAtla, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

KTTA
Pasithea Therapeutics Corp.
May 1, 2026
Award(A)
Stock Option (right to buy)
Direct
152.8K shares-
KTTA
Pasithea Therapeutics Corp.
Nov 28, 2025
Purchase(P)
Direct
133.3K shares at avg. $0.75$100K
KTTA
Pasithea Therapeutics Corp.
Oct 24, 2025
Award(A)
Stock Option (right to buy)
Direct
242.9K shares-
BCAB
BioAtla, Inc.
Jun 18, 2025
Award(A)
Direct
23.5K shares-
ATNF
180 Life Sciences Corp.
Jun 17, 2025
Award(A)
Direct
45K shares-
ATNF
180 Life Sciences Corp.
Jun 17, 2025
Award(A)
Direct
48.2K shares-
ATNF
180 Life Sciences Corp.
Feb 20, 2025
Award(A)
Direct
65K shares-

		Type	Shares	Price		Ownership
May 1, 2026	KTTA Pasithea Therapeutics Corp.	Award(A) Stock Option (right to buy)	152,783	-	-	Direct
Nov 28, 2025	KTTA Pasithea Therapeutics Corp.	Purchase(P)	133,333	$0.75	$100,000	Direct
Oct 24, 2025	KTTA Pasithea Therapeutics Corp.	Award(A) Stock Option (right to buy)	242,913	-	-	Direct
Jun 18, 2025	BCAB BioAtla, Inc.	Award(A)	23,500	-	-	Direct
Jun 17, 2025	ATNF 180 Life Sciences Corp.	Award(A)	44,959	-	-	Direct
Jun 17, 2025	ATNF 180 Life Sciences Corp.	Award(A)	48,198	-	-	Direct
Feb 20, 2025	ATNF 180 Life Sciences Corp.	Award(A)	65,000	-	-	Direct

1-7 of 7 transactions

About STEINMAN LAWRENCE

STEINMAN LAWRENCE (SEC CIK 0001132679) files insider reports with the SEC as Director of Pasithea Therapeutics Corp. (KTTA), Director of 180 Life Sciences Corp. (ATNF) and Director of BioAtla, Inc. (BCAB).

Signal8 holds 8 ownership filings by STEINMAN LAWRENCE, all Form 4s, filed between Feb 21, 2025 and May 5, 2026. Those filings report 7 transactions, from Feb 20, 2025 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on STEINMAN LAWRENCE's filings is in MIAMI BEACH, FL.

Recent filings by STEINMAN LAWRENCE

May 1, 2026: Grant or award of KTTA derivative securities (Form 4, code A).
Nov 28, 2025: Open-market purchase of KTTA shares (Form 4, code P).
Oct 24, 2025: Grant or award of KTTA derivative securities (Form 4, code A).
Jun 18, 2025: Grant or award of BCAB shares (Form 4, code A).
Jun 17, 2025: Grants or awards of ATNF shares (2 lines, Form 4, code A).

Other insiders filing for Pasithea Therapeutics Corp. (KTTA)

Coastlands Capital LP, 10% Owner
Marques Tiago, Chief Executive Officer
Dumesnil Simon, Director
Schneiderman Daniel H, Chief Financial Officer
Krishnan Kartik, Chief Medical Officer
Leahy Emer, Director

How to read Form 4 transaction codes